The Influence of Performance Status, Inflammation, and Nutrition on the Impact of <scp>SGLT2</scp> Inhibitors on Cancer Outcomes
Our results suggest that the impact of SGLT2i treatment on cancer outcomes is limited under standard clinical dosing conditions.
Authors
- Edelmiro Menéndez Torre (ORCID: https://orcid.org/0000-0002-9548-7821)
- Miguel García‐Villarino (ORCID: https://orcid.org/0000-0002-0186-2804)
- Diego Rivas‐Otero (ORCID: https://orcid.org/0000-0001-6119-8848)
- Carmen Lambert (ORCID: https://orcid.org/0000-0002-7929-4990)
- Paula Jiménez‐Fonseca (ORCID: https://orcid.org/0000-0003-4592-3813)
- Elías Delgado (ORCID: https://orcid.org/0000-0001-6114-9712)
- Pedro Pujante (ORCID: https://orcid.org/0000-0002-4146-0690)
- Tomás González‐Vidal (ORCID: https://orcid.org/0009-0006-9147-1757)
- Pablo Agüeria‐Cabal
- Guillermo Ramos‐Ruiz
Institutions
- Universidad de Oviedo (ES)
- Instituto de Salud Carlos III (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Hospital Universitario Central de Asturias (ES)
- Instituto de Investigación Sanitaria del Principado de Asturias (ES)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cam4.70807
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88